SOCS1 is a Critical Checkpoint in Immune Homeostasis, Inflammation and Tumor Immunity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jul 1

PMID 38947335

Authors

Grace M Bidgood

Narelle Keating

Karen Doggett

Sandra E Nicholson

Affiliations

Soon will be listed here.

Abstract

The Suppressor of Cytokine Signaling (SOCS) family proteins are important negative regulators of cytokine signaling. SOCS1 is the prototypical member of the SOCS family and functions in a classic negative-feedback loop to inhibit signaling in response to interferon, interleukin-12 and interleukin-2 family cytokines. These cytokines have a critical role in orchestrating our immune defence against viral pathogens and cancer. The ability of SOCS1 to limit cytokine signaling positions it as an important immune checkpoint, as evidenced by the detection of detrimental variants in patients with cytokine-driven inflammatory and autoimmune disease. SOCS1 has also emerged as a key checkpoint that restricts anti-tumor immunity, playing both a tumor intrinsic role and impacting the ability of various immune cells to mount an effective anti-tumor response. In this review, we describe the mechanism of SOCS1 action, focusing on the role of SOCS1 in autoimmunity and cancer, and discuss the potential for new SOCS1-directed cancer therapies that could be used to enhance adoptive immunotherapy and immune checkpoint blockade.

Citing Articles

Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling.

Chang T, Ho P Immune Netw. 2025; 25(1):e8.

PMID: 40078784 PMC: 11896656. DOI: 10.4110/in.2025.25.e8.

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.

Kashyap A, Dai J, Ni X Cancers (Basel). 2025; 17(4).

PMID: 40002165 PMC: 11853177. DOI: 10.3390/cancers17040568.

How (Ultra-)Rare Gene Variants Improve Our Understanding of More Common Autoimmune and Inflammatory Diseases.

Belot A, Tusseau M, Cognard J, Georgin-Lavialle S, Boursier G, Hedrich C ACR Open Rheumatol. 2025; 7(2):e70003.

PMID: 39964335 PMC: 11834591. DOI: 10.1002/acr2.70003.

IFN-τ Maintains Immune Tolerance by Promoting M2 Macrophage Polarization via Modulation of Bta-miR-30b-5p in Early Uterine Pregnancy in Dairy Cows.

Feng X, Yang C, Wang T, Zhang J, Zhou H, Ma B Cells. 2025; 14(2).

PMID: 39851515 PMC: 11764194. DOI: 10.3390/cells14020087.

Manipulating immune activity of macrophages: a materials and mechanics perspective.

Clevenger A, Jha A, Moore E, Raghavan S Trends Biotechnol. 2024; 43(1):131-144.

PMID: 39155172 PMC: 11717646. DOI: 10.1016/j.tibtech.2024.07.009.

References

Sharma J, Larkin 3rd J . Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer. Front Pharmacol. 2019; 10:324. PMC: 6499178. DOI: 10.3389/fphar.2019.00324. View

Hanada T, Yoshida H, Kato S, Tanaka K, Masutani K, Tsukada J . Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity. 2003; 19(3):437-50. DOI: 10.1016/s1074-7613(03)00240-1. View

Whyte C, Bishop E, Ruckerl D, Gaspar-Pereira S, Barker R, Allen J . Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol. 2011; 90(5):845-54. DOI: 10.1189/jlb.1110644. View

Fenner J, Starr R, Cornish A, Zhang J, Metcalf D, Schreiber R . Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol. 2005; 7(1):33-9. DOI: 10.1038/ni1287. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Curtsinger J, Agarwal P, Lins D, Mescher M . Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function. J Immunol. 2012; 189(2):659-68. PMC: 3392455. DOI: 10.4049/jimmunol.1102727. View

Krebs D, Uren R, Metcalf D, Rakar S, Zhang J, Starr R . SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002; 22(13):4567-78. PMC: 133908. DOI: 10.1128/MCB.22.13.4567-4578.2002. View

Ghazawi F, Faller E, Parmar P, El-Salfiti A, MacPherson P . Suppressor of cytokine signaling (SOCS) proteins are induced by IL-7 and target surface CD127 protein for degradation in human CD8 T cells. Cell Immunol. 2016; 306-307:41-52. DOI: 10.1016/j.cellimm.2016.07.002. View

Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H . Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021; 39(24):2656-2666. PMC: 8376325. DOI: 10.1200/JCO.21.00612. View

10.

Garg A, Rawat P, Spector S . Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression. J Infect Dis. 2014; 211(5):755-68. PMC: 4402373. DOI: 10.1093/infdis/jiu523. View

11.

Nagai H, Kim Y, Konishi N, Baba M, Kubota T, Yoshimura A . Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett. 2002; 186(1):59-65. DOI: 10.1016/s0304-3835(02)00244-6. View

12.

Hanada T, Tanaka K, Matsumura Y, Yamauchi M, Nishinakamura H, Aburatani H . Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J Immunol. 2005; 174(7):4325-32. DOI: 10.4049/jimmunol.174.7.4325. View

13.

Michniacki T, Walkovich K, DeMeyer L, Saad N, Hannibal M, Basiaga M . SOCS1 Haploinsufficiency Presenting as Severe Enthesitis, Bone Marrow Hypocellularity, and Refractory Thrombocytopenia in a Pediatric Patient with Subsequent Response to JAK Inhibition. J Clin Immunol. 2022; 42(8):1766-1777. PMC: 9381392. DOI: 10.1007/s10875-022-01346-x. View

14.

Eyles J, Metcalf D, Grusby M, Hilton D, Starr R . Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J Biol Chem. 2002; 277(46):43735-40. DOI: 10.1074/jbc.M208586200. View

15.

Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T . The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022; 13:950923. PMC: 9616161. DOI: 10.3389/fphar.2022.950923. View

16.

Jackson S, Yu C, Mahdi R, Ebong S, Egwuagu C . Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol. 2004; 172(4):2307-15. DOI: 10.4049/jimmunol.172.4.2307. View

17.

Liu B, Mink S, Wong K, Stein N, Getman C, Dempsey P . PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol. 2004; 5(9):891-8. DOI: 10.1038/ni1104. View

18.

Chiocchia G, Bessis N, Batteux F, Muller S, Huang S, Boissier M . High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol. 1997; 158(11):5501-6. View

19.

Thaventhiran J, Lango Allen H, Burren O, Rae W, Greene D, Staples E . Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020; 583(7814):90-95. PMC: 7334047. DOI: 10.1038/s41586-020-2265-1. View

20.

Sporri B, Kovanen P, Sasaki A, Yoshimura A, Leonard W . JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood. 2001; 97(1):221-6. DOI: 10.1182/blood.v97.1.221. View